Abstract: RNA transcripts representing a fusion of a human SLC45A3 nucleic acid and a human ELK4 nucleic acid that are associated with prostate cancer are described. Compositions and methods useful for detection of fusion transcripts of human SLC45A3 and ELK4 genetic sequences associated with cancer and useful for cancer therapy are provided.
Type:
Grant
Filed:
February 19, 2010
Date of Patent:
October 4, 2016
Assignee:
CORNELL UNIVERSITY
Inventors:
Mark A. Rubin, Dorothee Pflueger, David S. Rickman
Abstract: The present invention relates to a kit comprising a DNA-dependant DNA polymerase and at least one natural deoxynucleoside and to a kit comprising a DNA-dependent DNA polymerase and a detection system comprising a DNA template molecule, a DNA primer molecule, and a fluorescent moiety capable of being displaced from, or bound to, dsDNA synthesized by said DNA-dependent polymerase.
Abstract: This invention provides markers, methods, biochips and kits for milk quality detection. The present invention particularly provides a method for milk quality detection by means of detecting the particular microRNAs in milk, so as to establish the standard of raw milk content.
Type:
Grant
Filed:
May 27, 2010
Date of Patent:
August 30, 2016
Assignee:
JIANGSU MICROMEDMARK BIOTECH CO., LTD.
Inventors:
Chengyu Zhang, Ke Zeng, Junfeng Zhang, Chunliang Tian, Haijin Li
Abstract: A single nucleotide polymorphic site at position 10793 of the bovine POU1F1 gene is associated with improved longevity and milk product traits. Disclosed are nucleic acid molecules, kits, methods of genotyping and marker assisted bovine breeding methods.
Abstract: Method and compositions for screening for the presence of Epidermal Growth Factor Receptor variant 3 (EGFR(v3)) in a sample are described. The method comprises obtaining a sample containing a plurality of cells; hybridizing a set of chromosomal probes to the sample, wherein the set comprises an EGFR(v3)-probe and a probe to chromosome 7 different from an EGFR(v3)-probe; and visualizing the hybridization pattern of the set of chromosomal probes in the plurality of cells of the sample, wherein the presence of at least one copy of chromosome 7 lacking a hybridization signal of the EGFR(v3)-probe in at least one cell is indicative of the presence of the EGFR(v3) in the sample. The method and compositions are suitable for diagnosing the therapeutic outcome for treating a patient having a cancer with an anti-EGFR therapeutic agent and for screening a sample for a predisposition for forming an EGFR-associated cancer.
Type:
Grant
Filed:
December 27, 2012
Date of Patent:
August 9, 2016
Assignee:
Abbott Molecular Inc.
Inventors:
Susan S. Jewell, John C. Russell, Larry E. Morrison
Abstract: A method and kit are related to discriminating between breast cancer and benign breast disease by the determination of the expression level of at least one target gene including a nucleic acid sequence selected from the nucleic acid sequences set forth in SEQ ID NOs: 1, 2 or 3, 4 and 5 or 6 to obtain an expression profile for the patient, and the comparison of the expression profile of the patient with expression profiles of target genes from patients previously clinically classified as breast cancer and expression profiles of target genes from patients previously clinically classified as benign breast disease.
Type:
Grant
Filed:
May 28, 2010
Date of Patent:
August 9, 2016
Assignee:
BIOMERIEUX
Inventors:
Xun Ye, Fei Wu, Qinghua Xu, Xia Meng, Bruno Mougin
Abstract: The invention provides nucleic acids, collections of nucleic acids, supports, assay kits, and methods for the sensitive and specific detection of microorganisms in a foodstuff. The nucleic acid comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1-15 and having a length of no more than 35 nucleotides.
Abstract: The invention relates to cosmetic formulations. In one embodiment, the present invention relates to cosmetic formulations for use on the skin (e.g., the skin of the face).
Abstract: A novel gene (EPM2A) that is deleted or mutated in people with Lafora's disease is described. The EPM2A gene encodes a protein having an active catalytic site of a protein tyrosine phosphatase. Many different sequence mutations as well as several microdeletions in EPM2A have been found that co-segregate with Lafora's disease.
Type:
Grant
Filed:
June 24, 2013
Date of Patent:
May 10, 2016
Assignees:
The Hospital for Sick Children, McGill University, The Regents of the University of California, U.S. Department of Veterans Affairs
Inventors:
Stephen W. Scherer, Berge A. Minassian, Antonio Delgado-Escueta, Guy Rouleau
Abstract: The invention relates to the use of gene modifications in the human gene CHK2 (CHEK2), which encodes the checkpoint kinase 2, for predicting the risk and progression of cancer diseases, for predicting the response to pharmacological or non-pharmacological therapeutic measures for treating cancer diseases, and for predicting undesired effects of drugs. The invention further relates to the provision of individual gene variants with the help of which further gene modifications that can be used for the aforementioned purposes can be detected and validated. Such gene modifications can comprise a substitution of adenine for guanine in position ?7161 in the promoter of CHK2, a substitution of guanine for cytosine in position ?7235, a substitution of adenine for guanine in position ?10532, or a deletion of 29 base pairs in positions ?10621 to ?10649.
Abstract: The invention provides methods and compositions for noninvasive prenatal diagnosis of fetal aneuploidies. A large panel of differentially methylated regions (DMRs) have been identified. Certain of these DMRs are hypomethylated in adult female blood DNA and hypermethylated in fetal DNA, whereas others are hypermethylated in adult female blood DNA and hypomethylated in fetal DNA. Moreover, DMRs that are hypomethylated in adult female blood DNA and hypermethylated in fetal DNA have been shown to accurately predict a fetal aneuploidy in fetal DNA present in a maternal blood sample during pregnancy. In the methods of the invention, hypermethylated DNA is physically separated from hypomethylated DNA, preferably by methylated DNA immunoprecipitation.
Type:
Grant
Filed:
January 26, 2011
Date of Patent:
February 2, 2016
Assignee:
NIPD Genetics Ltd
Inventors:
Philippos C. Patsalis, Elisavet A. Papageorgiou
Abstract: The invention relates to methods and compositions for identifying and for selecting maize plants with mechanical stalk strength characteristics. The methods use molecular markers to identify and select plants with increased mechanical stalk strength or to identify and counter-select plants with decreased mechanical stalk strength. Maize plants generated by the methods of the invention are also a feature of the invention.
Type:
Grant
Filed:
June 10, 2013
Date of Patent:
January 5, 2016
Assignees:
E I DU PONT DE NEMOURS AND COMPANY, PIONEER HI-BRED INTERNATIONAL INC
Inventors:
Marymar Goncalves Butruille, Ada S Ching, Stanley Luck, J Antoni Rafalski
Abstract: The present invention is directed to a monoclonal antibody that recognizes human ING4 in its native form. The invention is also directed to a hybridoma cell line that produces the monoclonal antibody, and to methods of diagnosing cancer using the antibody.
Type:
Grant
Filed:
October 22, 2013
Date of Patent:
November 24, 2015
Assignees:
The Translational Genomics Research Institute, The Arizona Board of Regents on Behalf of the University of Arizona
Abstract: A method comprises magnetically holding a bead carrying biological material (e.g., nucleic acid, which may be in the form of DNA fragments or amplified DNA) in a specific location of a substrate, and applying an electric field local to the bead to isolate the biological material or products or byproducts of reactions of the biological material. For example, the bead is isolated from other beads having associated biological material. The electric field in various embodiments concentrates reagents for an amplification or sequencing reaction, and/or concentrates and isolates detectable reaction by-products. For example, by isolating nucleic acids around individual beads, the electric field can allow for clonal amplification, as an alternative to emulsion PCR. In other embodiments, the electric field isolates a nanosensor proximate to the bead, to facilitate detection of at least one of local pH change, local conductivity change, local charge concentration change and local heat.
Type:
Grant
Filed:
October 4, 2011
Date of Patent:
November 17, 2015
Assignee:
GENAPSYS, INC.
Inventors:
Hesaam Esfandyarpour, Mark F. Oldham, Eric S. Nordman, Kosar Baghbani Parizi
Abstract: The present invention relates to implantable medical devices coated with phosphoryl choline acrylate polymer topcoat layer and their use in the treatment of vascular diseases.
Abstract: A coating for implantable medical devices and a method for fabricating thereof are disclosed. The coating includes a mixture of a hydrophobic polymer and a polymeric hydrophilic additive, wherein the hydrophobic polymer and the hydrophilic additive form a physically entangled or interpenetrating system.
Abstract: A method for single-cycle selection of aptamers is provided. More specifically, a method comprising single-cycle selection of aptamers for proteins blotted on a membrane is provided. In some embodiments, the present methods can comprise a deoxyribonuclease I (DNase I) mediated aptamers selection strategy that may be capable of isolating strong binding aptamers for target proteins from a crude protein extract. Aptamers selected using the present method are further provided. More specifically, the presently selected aptamers may be thermally stable, modifiable and easily produced through single-cycle synthesis process. The present aptamers may provide unique affinity reagents for use in diagnosing and detecting infectious disease (for example Hepatitis B), for research and biochemical studies (e.g. into molecular mechanisms). Further, the present aptamers may be utilized to develop unique assays or kits for clinical application, such as monitoring disease treatment and outcome.
Type:
Grant
Filed:
August 28, 2013
Date of Patent:
October 6, 2015
Assignee:
The Governors of the University of Alberta
Abstract: Methods, compositions, systems, apparatus, and kits are provided for depositing samples onto surfaces. The samples can include one or more particles, and the surface can include one or more reaction chambers. In some embodiments, the depositing can include the use of companion particles in combination with sample particles.
Type:
Grant
Filed:
October 18, 2013
Date of Patent:
October 6, 2015
Assignee:
Life Technologies Corporation
Inventors:
Todd Rearick, Jessica Lynn Reed, Jason Gioia, Devin Dressman, Nicholas Hapshe, Brian Reed, John Andrew Sheridan
Abstract: Provided are SNP panels and methods that employ SNP panels for predicting prostate cancer-specific mortality in a human patient. Exemplary SNP panels presented herein comprise one or more of the SNPs designated rs1137100, rs228697, rs2839685, rs1799814, rs627839, rs5993891, rs635261, rs11710277, rs11205, rs2494750, rs4608577, rs4645959, rs1799964, rs25487, rs2308327, rs915927, rs2070874, rs1029153, rs12467911, rs10778534, rs523349, and rs4583514 and are exemplified by SNP panels comprising variant alleles in one or more of the SNPs designated rs1137100, rs2070874, rs10778534, rs627839, and rs5993891.